## Ammar M Almaaytah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6130137/publications.pdf

Version: 2024-02-01

516710 477307 39 874 16 29 g-index citations h-index papers 40 40 40 1240 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Scorpion venom peptides with no disulfide bridges: A review. Peptides, 2014, 51, 35-45.	2.4	139
2	Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria. Drug Design, Development and Therapy, 2017, Volume 11, 3159-3170.	4.3	74
3	Antimicrobial/cytolytic peptides from the venom of the North African scorpion, Androctonus amoreuxi: Biochemical and functional characterization of natural peptides and a single site-substituted analog. Peptides, 2012, 35, 291-299.	2.4	71
4	Dispensing of non-prescribed antibiotics in Jordan. Patient Preference and Adherence, 2015, 9, 1389.	1.8	65
5	Public knowledge and awareness of cardiovascular disease and its risk factors: a cross-sectional study of 1000 Jordanians. International Journal of Pharmacy Practice, 2012, 20, 367-376.	0.6	50
6	Antimicrobial and Antibiofilm Activity of UP-5, an Ultrashort Antimicrobial Peptide Designed Using Only Arginine and Biphenylalanine. Pharmaceuticals, $2018,11,3.$	3.8	38
7	Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides. Infection and Drug Resistance, 2018, Volume 11, 835-847.	2.7	33
8	Generation of the First Structure-Based Pharmacophore Model Containing a Selective "Zinc Binding Group―Feature to Identify Potential Glyoxalase-1 Inhibitors. Molecules, 2012, 17, 13740-13758.	3.8	30
9	Mauriporin, a Novel Cationic α-Helical Peptide with Selective Cytotoxic Activity Against Prostate Cancer Cell Lines from the Venom of the Scorpion Androctonus mauritanicus. International Journal of Peptide Research and Therapeutics, 2013, 19, 281-293.	1.9	30
10	Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. Pharmaceuticals, 2014, 7, 502-516.	3.8	30
11	Synergism of cationic antimicrobial peptide WLBU2 with antibacterial agents against biofilms of multi-drug resistant <em>Acinetobacter baumannii</em> and <em>Klebsiella pneumoniae</em> . Infection and Drug Resistance, 2019, Volume 12, 2019-2030.	2.7	26
12	Novel glyoxalase-I inhibitors possessing a & amp; Idquo; zinc-binding feature & amp; rdquo; as potential anticancer agents. Drug Design, Development and Therapy, 2016, Volume 10, 2623-2629.	4.3	19
13	A3, a Scorpion Venom Derived Peptide Analogue with Potent Antimicrobial and Potential Antibiofilm Activity against Clinical Isolates of Multi-Drug Resistant Gram Positive Bacteria. Molecules, 2018, 23, 1603.	3.8	19
14	Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents. Computational Biology and Chemistry, 2019, 80, 102-110.	2.3	19
15	Recent Advances in Glyoxalase-I Inhibition. Mini-Reviews in Medicinal Chemistry, 2019, 19, 281-291.	2.4	19
16	Virtual Lead Identification of Farnesyltransferase Inhibitors Based on Ligand and Structure-Based Pharmacophore Techniques. Pharmaceuticals, 2013, 6, 700-715.	3.8	18
17	Prevalence and nature of off-label antibiotic prescribing for children in a tertiary setting: A descriptive study from Jordan. Pharmacy Practice, 2016, 14, 725.	1.5	18
18	<p>Design and characterization of a new hybrid peptide from LL-37 and BMAP-27</p> . Infection and Drug Resistance, 2019, Volume 12, 1035-1045.	2.7	17

#	Article	IF	Citations
19	Antimicrobial and Antibiofilm Activity of Mauriporin, a Multifunctional Scorpion Venom Peptide. International Journal of Peptide Research and Therapeutics, 2014, 20, 397-408.	1.9	16
20	<p>The evaluation of the synergistic antimicrobial and antibiofilm activity of AamAP1-Lysine with conventional antibiotics against representative resistant strains of both Gram-positive and Gram-negative bacteria</p> . Infection and Drug Resistance, 2019, Volume 12, 1371-1380.	2.7	16
21	Peptide consensus sequence determination for the enhancement of the antimicrobial activity and selectivity of antimicrobial peptides. Infection and Drug Resistance, 2017, Volume 10, 1-17.	2.7	15
22	Oral Delivery of Teriparatide Using a Nanoemulsion System: Design, in Vitro and in Vivo Evaluation. Pharmaceutical Research, 2020, 37, 80.	3.5	13
23	The Design and Functional Characterization of the Antimicrobial and Antibiofilm Activities of BMAP27-Melittin, a Rationally Designed Hybrid Peptide. International Journal of Peptide Research and Therapeutics, 2015, 21, 165-177.	1.9	12
24	In Vitro Synergistic Activities of the Hybrid Antimicrobial Peptide MelitAP-27 in Combination with Conventional Antibiotics Against Planktonic and Biofilm Forming Bacteria. International Journal of Peptide Research and Therapeutics, 2016, 22, 497-504.	1.9	12
25	Computational and experimental exploration of the structure–activity relationships of flavonoids as potent glyoxalaseâ€i inhibitors. Drug Development Research, 2018, 79, 58-69.	2.9	11
26	The Design of Alapropoginine, a Novel Conjugated Ultrashort Antimicrobial Peptide with Potent Synergistic Antimicrobial Activity in Combination with Conventional Antibiotics. Antibiotics, 2021, 10, 712.	3.7	10
27	Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold. Acta Pharmaceutica, 2021, 71, 115-130.	2.0	10
28	Multi-Armed 1,2,3-Selenadiazole and 1,2,3-Thiadiazole Benzene Derivatives as Novel Glyoxalase-I Inhibitors. Molecules, 2019, 24, 3210.	3.8	8
29	Novel N-substituted aminobenzamide scaffold derivatives targeting the dipeptidyl peptidase-IV enzyme. Drug Design, Development and Therapy, 2014, 8, 129.	4.3	6
30	Identification of Possible Glyoxalase II Inhibitors as Anticancer Agents by a Customized 3D Structure - Based Pharmacophore Model = ØªØØ¯ÙŠØ¯ مثبطات Ù…ØØªÙ…لة لإنزيم الذليI	ù^th <del>}</del> ø³ø!	§ù"ûšø² 2 ù.
31	In vivo antimicrobial activity of the hybrid peptide H4: a follow-up study. Infection and Drug Resistance, 2018, Volume 11, 1383-1386.	2.7	5
32	Functional Characterization of a Novel Hybrid Peptide with High Potency against Gram-negative Bacteria. Current Pharmaceutical Design, 2020, 26, 376-385.	1.9	4
33	Current Status of Biosimilar Regulations in the MENA Region. International Journal of Research in Pharmaceutical Sciences, 2020, 11, 3443-3449.	0.1	3
34	Pretreatment with Salvadora persica L. (Miswak) aqueous extract alleviates paracetamol-induced hepatotoxicity, nephrotoxicity, and hematological toxicity in male mice. Veterinary World, 2021, 14, 589-594.	1.7	2
35	Immunodiagnosis of cattle fascioliasis using a 27 kDa Fasciola gigantica antigen. Veterinary World, 2021, 14, 2097-2101.	1.7	2
36	Production, immunogenicity, stability, and safety of a vaccine against Clostridium perfringens beta toxins. Veterinary World, 2020, 13, 1517-1523.	1.7	2

#	Article	lF	CITATIONS
37	Comparative Cost Efficiency of the Originator Drug of Infliximab and its Biosimilar for the Treatment of Rheumatoid Arthritis in the MENA Region. International Journal of Pharmaceutical Investigation, 2019, 9, 12-15.	0.3	1
38	Differential expression of glycogen synthase kinase $3\hat{l}_{\pm}$ and $3\hat{l}_{\pm}^{2}$ isomers in brain cortex of mice following high doses of glucose. International Journal of Research in Pharmaceutical Sciences, 2020, 11, 993-999.	0.1	1
39	TECHNICAL GUIDANCE ON THE PHYSICOCHEMICAL AND FUNCTIONAL COMPARABILITY EXERCISE FOR TRASTUZUMAB BIOSIMILARS. International Journal of Applied Pharmaceutics, 0, , 71-76.	0.3	0